Diarrhea is a recurrent symptom in patients with neuroendocrine tumors (NETs) and can represent different etiologies; thus, differential diagnosis is challenging. This paper distinguishes the different causes of chronic diarrhea in patients with gastroenteropancreatic NETs, with the aim to identify the most appropriate therapeutic approach. Underlying causes of diarrhea can be multifactorial, including not only diarrhea that is related to specific hormonal hypersecretory syndromes, but also diarrhea that is secondary to the following extensive surgery which can cause pancreatic exocrine insufficiency or short bowel syndrome, treatment with somatostatin analogs or other antineoplastic agents, and bile acid malabsorption. After initial management of diarrhea with general treatments (dietary modification, use of antidiarrheals), a proper differential diagnosis is necessary to treat patients with specific etiology-driven therapeutic approaches, such as somatostatin analogs, pancreatic enzyme replacement therapy, and tryptophan hydroxylase inhibitors. In conclusion, NETs should be considered in the differential diagnosis of patients suffering from chronic diarrhea, after the exclusion of more common etiologies. Furthermore, physicians should keep in mind that several different etiologies might be responsible for diarrhea occurrence in NET patients. A prompt diagnosis of the actual cause of diarrhea is necessary to guide the treatment and a multidisciplinary approach is mandatory.To accurately and quantitatively detect the gear pitting of different levels on the actual site, this paper studies a new vision measurement approach based on a tunable vision detection platform and the mask region-based convolutional neural network (Mask R-CNN). The shooting angle can be properly set according to the specification of the target gear. With the obtained sample set of 1500 gear pitting images, an optimized deep Mask R-CNN was designed for the quantitative measurement of gear pitting. The effective tooth surface and pitting was firstly and simultaneously recognized, then they were segmented to calculate the pitting area ratio. https://www.selleckchem.com/products/bmh-21.html Considering three situations of multi-level pitting, multi-illumination, and multi-angle, several indexes were used to evaluate detection and segmentation results of deep Mask R-CNN. Experimental results show that the proposed method has higher measurement accuracy than the traditional method based on image processing, thus it has significant practical potential.Malignant Pleural Mesothelioma (MPM) is an aggressive tumor of the pleural lining that is usually identified at advanced stages and resistant to current therapies. Appropriate pre-clinical mouse tumor models are of pivotal importance to study its biology. Usually, tumor cells have been injected intraperitoneally or subcutaneously. Using three available murine mesothelioma cell lines with different histotypes (sarcomatoid, biphasic, epithelioid), we have set up a simplified model of in vivo growth orthotopically by inoculating tumor cells directly in the thorax with a minimally invasive procedure. Mesothelioma tumors grew along the pleura and spread on the superficial areas of the lungs, but no masses were found outside the thoracic cavity. As observed in human MPM, tumors were highly infiltrated by macrophages and T cells. The luciferase-expressing cells can be visualized in vivo by bioluminescent optical imaging to precisely quantify tumor growth over time. Notably, the bioluminescence signal detected in vivo correctly matched the tumor burden quantified with classical histology. In contrast, the subcutaneous or intraperitoneal growth of these mesothelioma cells was considered either non-representative of the human disease or unreliable to precisely quantify tumor load. Our non-invasive in vivo model of mesothelioma is simple and reproducible, and it reliably recapitulates the human disease. Muscle synergy analysis is an approach to understand the neurophysiological mechanisms behind the hypothesized ability of the Central Nervous System (CNS) to reduce the dimensionality of muscle control. The muscle synergy approach is also used to evaluate motor recovery and the evolution of the patients' motor performance both in single-session and longitudinal studies. Synergy-based assessments are subject to various sources of variability natural trial-by-trial variability of performed movements, intrinsic characteristics of subjects that change over time (e.g., recovery, adaptation, exercise, etc.), as well as experimental factors such as different electrode positioning. These sources of variability need to be quantified in order to resolve challenges for the application of muscle synergies in clinical environments. The objective of this study is to analyze the stability and similarity of extracted muscle synergies under the effect of factors that may induce variability, including inter- and intra-sessiog results from multi-session assessments. Lastly, electrode positioning might play an important role in the lower similarity of synergies over different sessions.Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.The desmoid tumor is a locally aggressive proliferative disease within the family of soft-tissue sarcomas. Despite its relatively good prognosis, the clinical management of desmoid tumors requires constant multidisciplinary evaluation due to its highly variable clinical behavior. Recently, active surveillance has being regarded as the appropriate strategy at diagnosis, as indolent persistence or spontaneous regressions are not uncommon. Here, we review the most recent advances in desmoid tumor therapy, including low-dose chemotherapy and treatment with tyrosine kinase inhibitors. We also explore the recent improvements in our knowledge of the molecular biology of this disease, which are leading to clinical trials with targeted agents.